logo
Can adults make new brain cells? New study may finally settle one of neuroscience's greatest debates

Can adults make new brain cells? New study may finally settle one of neuroscience's greatest debates

Yahoo3 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Researchers say they have found clear evidence that the human brain can keep making new neurons well into adulthood, potentially settling decades of controversy.
This new neuron growth, or "neurogenesis," takes place in the hippocampus, a critical part of the brain involved in learning, memory and emotions.
"In short, our work puts to rest the long-standing debate about whether adult human brains can grow new neurons," co-lead study author Marta Paterlini, a researcher at the Karolinska Institute in Stockholm, told Live Science in an email.
Other experts agree that the work makes a strong case for adult neurogenesis.
While a single study does not constitute absolute proof, "this is strong evidence in support of the idea" that stem cells and precursors to new neurons exist and are proliferating in the adult human brain, said Dr. Rajiv Ratan, CEO of the Burke Neurological Institute at Weill Cornell Medicine, who was not involved in the study.
"This is a perfect example of great science teeing up the ball for the clinical neuroscience community," he told Live Science.
Related: Babies' brain activity changes dramatically before and after birth, groundbreaking study finds
The researchers combined advanced techniques, including single-nucleus RNA sequencing and machine learning, to sort and examine brain tissue samples from international biobanks, they reported in a paper published July 3 in the journal Science. RNA, a cousin of DNA, reflects genes that are "switched on" inside cells, while machine learning is a type of artificial intelligence often used to crunch huge datasets.
Since the 1960s, researchers have known that mice, rats and some nonhuman primates make new brain cells in the dentate gyrus, part of the hippocampus, throughout life. But getting quality brain tissue samples from adult humans is extremely challenging.
"Human tissue comes from autopsies or surgeries, so how it's handled — how long before it's fixed in preservative, which chemicals are used, how thin the slices are — can hide those newborn cells," Paterlini said. Employing new technologies enabled the team to overcome this challenge.
They analyzed more than 400,000 individual nuclei of hippocampus cells from 24 people, and in addition, looked at 10 other brains using other techniques. The brains came from people ages 0 to 78, including six children and four teens.
Using two cutting-edge imaging methods, the team mapped where new cells sat in the tissue. They saw groups of dividing precursor cells sitting right next to the fully formed neurons, in the same spots where animal studies have shown that adult stem cells reside.
"We didn't just see these dividing precursor cells in babies and young kids — we also found them in teenagers and adults," Paterlini said. "These include stem cells that can renew themselves and give rise to other brain cells."
The newer technologies enabled the researchers to detect the new brain cells at various stages of development and conduct research that wouldn't have been possible a few years ago, Ratan added.
The team also used fluorescent tags to mark the proliferating cells. This enabled them to build a machine learning algorithm that identified the cells that they knew would turn into neurogenic stem cells, based on past rodent studies. This was a "clever approach" for tackling the challenges of studying brain-cell formation in adolescents and adults, Ratan said.
As expected, the brains of children produced more new brain cells than the brains of adolescents or adults did. Meanwhile, nine out of 14 adult brains analyzed with one technique showed signs of neurogenesis, while 10 out of 10 adult brains analyzed with a second technique bore new cells. Regarding the few brains with no new cells, Paterlini said it's too soon to draw conclusions about the disparity between adult brains with evidence of new cells and those without.
RELATED STORIES
—How much of your brain do you need to survive?
—You're born with most of your neurons — but the brain makes some mysterious new ones in adulthood
—Brain aging accelerates dramatically around age 44 — could ketone supplements help?
Next, the researchers could explore whether the adults who produced new brain cells did so in response to a neurological disease, such as Alzheimer's, or whether adult neurogenesis is a sign of good brain health, said Dr. W. Taylor Kimberly, chief of neurocritical care at Massachusetts General Brigham, who was not involved in the study.
"They were able to find these needles in a haystack," Kimberly told Live Science. "Once you detect them and learn about them and understand their regulation," scientists can research how to track the precursor cells through time and see how their presence relates to disease, he said.
He envisioned comparing patients who have dementia to "super agers" who are cognitively resilient in old age. If the link between neurogenesis and disease can be uncovered, perhaps that could open the door to treatments.
"Although the precise therapeutic strategies in humans are still under active research," Paterlini said, "the very fact that our adult brains can sprout new neurons transforms how we think about lifelong learning, recovery from injury and the untapped potential of neural plasticity."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rebuilding Cancer Care from the Ground Up
Rebuilding Cancer Care from the Ground Up

Entrepreneur

time17 minutes ago

  • Entrepreneur

Rebuilding Cancer Care from the Ground Up

Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. In healthcare, timing is everything. But for Kelly McCabe, co-founder of Perci Health and a former oncology clinician, the real urgency lay not in the cancer treatments themselves - but in what was being left behind. "After 15 years working in cancer care, I saw firsthand how fractured and reactive the system was," McCabe says. "People received excellent treatment for their cancer, but everything else was fragmented or missing altogether." Side effects. Mental health. Long-term fatigue. The emotional and physical ripple effects of cancer often remain unaddressed, even as survival rates improve. It was that disconnect that drove McCabe to rethink what post-treatment support could - and should - look like. "No one was joining the dots between early risk factors, side effects, mental health, fatigue, or what happens after treatment ends," she adds. "The system wasn't built to support the whole person. Survivorship numbers were rising, but outcomes weren't improving." That insight led to the launch of Perci Health, a virtual cancer survivorship clinic offering personalised, multidisciplinary care beyond the hospital walls. The timing, McCabe says, crystallised when she met her co-founder, Morgan. n"She brought a deep understanding of digital transformation and consumer behaviour; skills I knew were essential to building something that was not only clinically rigorous but also scalable, accessible, and genuinely patient-first." Together, they built what McCabe says the system "wasn't going to build for us." AI With a Human Touch Unlike many digital health companies rushing to automate care, Perci is using AI to augment clinical expertise, not replace it. "We're using AI to move from reactive to truly proactive personalised care," McCabe explains. "Our platform continuously captures symptom, behavioural, and clinical data to adapt each person's care plan in real time." This means patients are matched with specialists - from psychologists to fatigue experts - according to their evolving needs. "This isn't about replacing clinical judgement; it's about scaling it," she says. "AI allows us to deliver bespoke care at scale, ensuring people don't just survive cancer - they recover well, return to life, and avoid preventable complications." The Trust Factor Still, scaling a virtual clinic in a highly regulated space comes with high stakes - and high expectations. For Perci, building trust wasn't a marketing task. It was structural. "From day one, we built Perci as a healthcare provider, not a wellness app," McCabe says. "That meant robust clinical governance, evidence-based care, and a specialist-only team." Perci's model, while medically grounded, has also required re-education. "Cancer is not yet seen as a chronic condition and our approach is a novel way to manage complex side effects," she adds. "It's taken real focus to make our model clear without oversimplifying what is a very sophisticated, multi-specialist approach." Redefining Leadership McCabe's own journey as a founder includes an experience still rarely discussed in startup circles: raising investment while pregnant. "It taught me what real leadership looks like," she reflects. "Leadership isn't about doing everything yourself, it's about building the kind of team and culture that can carry momentum, even when you need to step back." She credits both her co-founder and Perci's investors for creating the conditions for that to be possible. "That kind of support is essential when you're doing something innovative, and often, uncomfortable for the status quo." It also reframed her view of leadership itself. "Raising while pregnant showed me that leadership doesn't have to follow traditional patterns. It can be shared. It can be vulnerable. And it can be stronger because of it." Backing by Macmillan - and What It Signals A major milestone came when Macmillan Cancer Support invested in Perci through its Innovation Impact Fund. "It was a huge moment, for us and for the sector," McCabe says. "Their investment wasn't just capital, it was a vote of confidence in clinically grounded, tech-enabled models that address the human side of cancer." To her, the partnership represents a broader shift in the ecosystem. "It signals a shift: the idea that charities and digital health companies don't sit on opposite sides of the table anymore. We're both working toward better outcomes and increasingly, we're doing it together." A System Still in Progress Despite Perci's momentum, McCabe is clear-eyed about the complexities of healthcare innovation - and the patience it demands. "You can't assume the system is set up to pay for the kind of innovation you're building," she says. "We've had to reimagine how value is measured, how outcomes are proven, and how care gets paid for." The advice she gives to other founders in slow-moving sectors? Don't fight the system - work with it. "Respect the complexity of healthcare. Build evidence as you go. And stay open to new models that might not exist yet, but will, if you're willing to build them with the right people."

Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials

Yahoo

time9 hours ago

  • Yahoo

Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials

Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on

Neanderthals extracted animal fat in advanced food prep 'fat factories' 125,000 years ago: report
Neanderthals extracted animal fat in advanced food prep 'fat factories' 125,000 years ago: report

Yahoo

time11 hours ago

  • Yahoo

Neanderthals extracted animal fat in advanced food prep 'fat factories' 125,000 years ago: report

Neanderthals living 125,000 years ago in what is now modern-day Germany may have extracted and eaten fat from animal bones through an organized food preparation process that scientists describe as a "fat factory." While excavating the site of a former lake landscape called Neumark-Nord, archaeologists discovered thousands of bones from at least 172 large mammals, along with flint artifacts. The bones, which date back to an interglacial period in which Neanderthals lived, were from animals like red deer and horses, according to a study published on July 2 in Science Advances. While many of the bones that contained less bone marrow were spread out across the archaeological site, researchers observed that many of the marrow-rich bones were located in clusters — sites they call "fat factories." Rare Christian Cross Among Spectacular 1,000-Year-old Viking Treasures Found By Metal Detectorists Researchers believe our extinct ancestors used tools to smash the bones into small fragments and then boiled them for hours. The grease, which then floated to the surface of the water, could be skimmed off the top and eaten — providing a calorie-dense food source for the archaic people. Viking-era Burial Site With Elite Family Treasures And Gifts Discovered, Plus An 'Unusual Casket' Read On The Fox News App Prior to this, evidence of the practice had only dated back to 28,000 years ago, according to the research. "Neanderthals were clearly managing resources with precision — planning hunts, transporting carcasses, and rendering fat in a task-specific area," Dr. Lutz Kindler, the study's first author, said. "They understood both the nutritional value of fat and how to access it efficiently — most likely involving caching carcass parts at places in the landscape for later transport to and use at the grease rendering site. Mysterious 'Dumped' Bodies Of Woman And Child Found By Archaeologists In Picturesque Town Fat was a "life-sustaining" resource for Neanderthals, especially during the winter and spring seasons when carbohydrates were scarce. Their diets consisted largely of animal protein, and consuming lots of protein without other nutrients could lead to a sometimes deadly condition called protein poisoning, the research noted. "The sheer size and extraordinary preservation of the Neumark-Nord site complex gives us a unique chance to study how Neanderthals impacted their environment, both animal and plant life," Dr. Fulco Scherjon, data manager and computer scientist on the project, said. "That's incredibly rare for a site this old—and it opens exciting new possibilities for future research." In recent years, scientists have also discovered that Neanderthals went diving for seashells that they could chip with stone hammers into thin and sharp cutting edges. Similarly, another study suggested Neanderthals may have buried their dead with flowers. Researchers Lutz Kindler and Wil Roebroeks did not immediately respond to Fox News Digital's request for article source: Neanderthals extracted animal fat in advanced food prep 'fat factories' 125,000 years ago: report

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store